Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa

Pharmacogenomics Journal

Volumn 17, Issue 2, 2017, Pages 112-120

  Baker, J L ^a   Shriner, D ^a   Bentley, A R ^a   Rotimi, C N ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMODIAQUINE; ANTIRETROVIRUS AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; BENFLUMETOL; CHLOROQUINE; EFAVIRENZ; EFLORNITHINE; ETHAMBUTOL; INDINAVIR; ISONIAZID; LOPINAVIR; MARAVIROC; MEFLOQUINE; MELARSOPROL; NELFINAVIR; NEVIRAPINE; PENTAMIDINE; PRIMAQUINE; PYRAZINAMIDE; PYRIMETHAMINE PLUS SULFADOXINE; RIBAVIRIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SURAMIN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ANTIINFECTIVE AGENT;

AFRICA; AFRICAN TRYPANOSOMIASIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSPORT; GENE FREQUENCY; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; INCIDENCE; INFECTION; LASSA FEVER; LIVER TOXICITY; MALARIA; MALARIA CONTROL; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; REVIEW; TUBERCULOSIS; BLACK PERSON; COMMUNICABLE DISEASES; GENETIC VARIATION; GENETICS; GENOTYPE; MOLECULAR EVOLUTION; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHENOTYPE; TRANSMISSION; TREATMENT OUTCOME;

AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; EVOLUTION, MOLECULAR; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; TREATMENT OUTCOME;

EID: 84992386152     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.78     Document Type: Review

References (202)

1. Campbell MC, Tishkoff SA. The evolution of human genetic and phenotypic variation in Africa. Curr Biol 2010; 20: R166-R173.
2. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008; 9: 403-433.
3. Amos W, Hoffman JI. Evidence that two main bottleneck events shaped modern human genetic diversity. Proc Biol Sci 2010; 277: 131-137.
4. Harpending H, Rogers A. Genetic perspectives on human origins and differentiation. Annu Rev Genomics Hum Genet 2000; 1: 361-385.
5. Ramachandran S, Deshpande O, Roseman CC, Rosenberg NA, Feldman MW, Cavalli-Sforza LL. Support from the relationship of genetic and geographic distance in human populations for a serial founder effect originating in Africa. Proc Natl Acad Sci USA 2005; 102: 15942-15947.
6. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO et al. A global reference for human genetic variation. Nature 2015; 526: 68-74.
7. Balaresque PL, Ballereau SJ, Jobling MA. Challenges in human genetic diversity: demographic history and adaptation. Hum Mol Genet 2007; 16 (Spec No. 2): R134-R139.
8. Fumagalli M, Sironi M, Pozzoli U, Ferrer-Admetlla A, Pattini L, Nielsen R. Signatures of environmental genetic adaptation pinpoint pathogens as the main selective pressure through human evolution. PLoS Genet 2011; 7: e1002355.
9. Tyler-Smith C, Yang H, Landweber LF, Dunham I, Knoppers BM, Donnelly P et al. Where next for genetics and genomics? PLoS Biol 2015; 13: e1002216.
10. Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell 2013; 155: 27-38.
11. Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem 2013; 6: 287-303.
12. Li JZ, Absher DM, Tang H, Southwick AM, Casto AM, Ramachandran S et al. Worldwide human relationships inferred from genome-wide patterns of variation. Science 2008; 319: 1100-1104.
13. Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA et al. Genetic structure of human populations. Science 2002; 298: 2381-2385.
14. Shriner D, Tekola-Ayele F, Adeyemo A, Rotimi CN. Genome-wide genotype and sequence-based reconstruction of the 140,000 year history of modern human ancestry. Sci Rep 2014; 4: 6055.
15. Rowell JL, Dowling NF, Yu W, Yesupriya A, Zhang L, Gwinn M. Trends in population-based studies of human genetics in infectious diseases. PLoS One 2012; 7: e25431.
16. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464-467.
17. Muenke M. Individualized genomics and the future of translational medicine. Mol Genet Genomic Med 2013; 1: 1-3.
18. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res 2009; 154: 277-287.
19. Adeyemo A, Rotimi C. What does genomic medicine mean for diverse populations? Mol Genet Genomic Med 2014; 2: 3-6.
20. Need AC, Goldstein DB. Next generation disparities in human genomics: concerns and remedies. Trends Genet 2009; 25: 489-494.
21. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009; 106: 9362-9367.
22. Chen MS Jr., Lara PN, Dang JH, Paterniti DA, Kelly K. Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. Cancer 2014; 120 (Suppl 7): 1091-1096.
23. Burchard EG, Oh SS, Foreman MG, Celedon JC. Moving toward true inclusion of racial/ethnic minorities in federally funded studies. A key step for achieving respiratory health equality in the United States. Am J Respir Crit Care Med 2015; 191: 514-521.
24. Oh SS, Galanter J, Thakur N, Pino-Yanes M, Barcelo NE, White MJ et al. Diversity in clinical and biomedical research: a promise yet to be fulfilled. PLoS Med 2015; 12: e1001918.
25. Pillai G, Davies G, Denti P, Steimer JL, McIlleron H, Zvada S et al. Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa. CPT Pharmacometrics Syst Pharmacol 2013; 2: e69.
26. Adeyemo A, Rotimi C. Genetic variants associated with complex human diseases show wide variation across multiple populations. Public Health Genomics 2010; 13: 72-79.
27. Ntzani EE, Liberopoulos G, Manolio TA, Ioannidis JP. Consistency of genome-wide associations across major ancestral groups. Hum Genet 2012; 131: 1057-1071.
28. Carlson CS, Matise TC, North KE, Haiman CA, Fesinmeyer MD, Buyske S et al. Generalization and dilution of association results from European GWAS in populations of non-European ancestry: the PAGE study. PLoS Biol 2013; 11: e1001661.
29. Ramos E, Doumatey A, Elkahloun AG, Shriner D, Huang H, Chen G et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J 2014; 14: 217-222.
30. Chen R, Corona E, Sikora M, Dudley JT, Morgan AA, Moreno-Estrada A et al. Type 2 diabetes risk alleles demonstrate extreme directional differentiation among human populations, compared to other diseases. PLoS Genet 2012; 8: e1002621.
31. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A et al. The genetic structure and history of Africans and African Americans. Science 2009; 324: 1035-1044.
32. Cashdan E. Ethnic diversity and its environmental determinants: effects of climate, pathogens, and habitat diversity. Am Anthropol 2001; 103: 968-991.
33. Gurdasani D, Carstensen T, Tekola-Ayele F, Pagani L, Tachmazidou I, Hatzikotoulas K et al. The African Genome Variation Project shapes medical genetics in Africa. Nature 2015; 517: 327-332.
34. Kerb R, Fux R, Morike K, Kremsner PG, Gil JP, Gleiter CH et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis 2009; 9: 760-774.
35. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392: 1093-1108.
36. Tekola-Ayele F, Adeyemo A, Aseffa A, Hailu E, Finan C, Davey G et al. Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population. Pharmacogenomics J 2015; 15: 101-108.
37. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441-446.
38. Bernal ML, Sinues B, Johansson I, McLellan RA, Wennerholm A, Dahl ML et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 1999; 9: 657-660.
39. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
40. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229-243.
41. FDA Drug Safety Communication. Available at http://wwwfdagov/Drugs/Drug Safety/ucm339112htm (accessed on 20 February 2013).
42. Anberbir Y. Ethiopia: Authority Issues Red Alert On Codeine Drug. Available at: http://allafrica.com/stories/201511241318.html (accessed on 21 November 2015).
43. Hoehe MR, Kroslak T. Genetic variation and pharmacogenomics: concepts, facts, and challenges. Dialogues Clin Neurosci 2004; 6: 5-26.
44. Ma Q, Lu AY. Pharmacogenetics pharmacogenomics, and individualized medicine. Pharmacol Rev 2011; 63: 437-459.
45. Li J, Zhang L, Zhou H, Stoneking M, Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Hum Mol Genet 2011; 20: 528-540.
46. Rotimi C, Abayomi A, Abimiku A, Adabayeri VM, Adebamowo C, Adebiyi E et al. Research capacity. Enabling the genomic revolution in Africa. Science 2014; 344: 1346-1348.
47. Wonkam A, Mayosi BM. Genomic medicine in Africa: promise, problems and prospects. Genome Med 2014; 6: 11.
48. de Vries J, Tindana P, Littler K, Ramsay M, Rotimi C, Abayomi A et al. The H3Africa policy framework: negotiating fairness in genomics. Trends Genet 2015; 31: 117-119.
49. Siwo GH, Williams SM, Moore JH. The future of genomic medicine education in Africa. Genome Med 2015; 7: 47.
50. World Health Organization. World Malaria Report 2015. Geneva, Switzerland 2015 Available at http://appswhoint/iris/bitstream/10665/200018/1/ 9789241565158-engpdf?ua = 1 (accessed on 2 February 2016).
51. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008; 5: e38.
52. Howes RE, Reiner RC Jr., Battle KE, Longbottom J, Mappin B, Ordanovich D et al. Plasmodium vivax transmission in Africa. PLoS Negl Trop Dis 2015; 9: e0004222.
53. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001; 64 (1-2 Suppl): 97-106.
54. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 1976; 295: 302-304.
55. Langhi DM Jr., Bordin JO. Duffy blood group and malaria. Hematology 2006; 11: 389-398.
56. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012; 6: e1814.
57. Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW et al. The global distribution of the Duffy blood group. Nat Commun 2011; 2: 266.
58. Menard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci USA 2010; 107: 5967-5971.
59. Cavasini CE, Mattos LC, Couto AA, Bonini-Domingos CR, Valencia SH, Neiras WC et al. Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception? Trans R Soc Trop Med Hyg 2007; 101: 1042-1044.
60. Wassmer SC, Taylor TE, Rathod PK, Mishra SK, Mohanty S, Arevalo-Herrera M et al. Investigating the pathogenesis of severe malaria: a multidisciplinary and cross-geographical approach. Am J Trop Med Hyg 2015; 93 (3 Suppl): 42-56.
61. Pasvol G, Weatherall DJ, Wilson RJ. Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria. Nature 1978; 274: 701-703.
62. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA et al. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352: 595-600.
63. Fumagalli M, Cagliani R, Pozzoli U, Riva S, Comi GP, Menozzi G et al. Widespread balancing selection and pathogen-driven selection at blood group antigen genes. Genome Res 2009; 19: 199-212.
64. Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J 1954; 1: 290-294.
65. Aidoo M, Terlouw DJ, Kolczak MS, McElroy PD, ter Kuile FO, Kariuki S et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359: 1311-1312.
66. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun 2010; 1: 104.
67. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 2013; 81: 133-201.
68. Bienzle U, Ayeni O, Lucas AO, Luzzatto L. Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant. Lancet 1972; 1: 107-110.
69. Tishkoff SA, Varkonyi R, Cahinhinan N, Abbes S, Argyropoulos G, Destro-Bisol G et al. Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance. Science 2001; 293: 455-462.
70. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 2012; 9: e1001339.
71. Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquinesensitive erythrocytes. Science 1956; 124: 484-485.
72. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J 2013; 12: 391.
73. Shahinas D, Folefoc A, Pillai DR. Targeting Plasmodium falciparum Hsp90: towards reversing antimalarial resistance. Pathogens 2013; 2: 33-54.
74. World Health Organization. Guidelines for the treatment of malaria. 2015; Third edition. Available at: http://www.who.int/malaria/publications/atoz/ 9789241549127/en/ (accessed on 10 October 2016).
75. Ogbonna A, Uneke CJ. Artemisinin-based combination therapy for uncomplicated malaria in sub-Saharan Africa: the efficacy, safety, resistance and policy implementation since Abuja 2000. Trans R Soc Trop Med Hyg 2008; 102: 621-627.
76. Roederer MW, McLeod H, Juliano JJ. Can pharmacogenomics improve malaria drug policy? Bull World Health Organ 2011; 89: 838-845.
77. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 2004; 71 (2 Suppl): 179-186.
78. Hyde JE. Drug-resistant malaria-an insight. FEBS J 2007; 274: 4688-4698.
79. Mehlotra RK, Henry-Halldin CN, Zimmerman PA. Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics 2009; 10: 435-449.
80. Dandara C, Swart M, Mpeta B, Wonkam A, Masimirembwa C. Cytochrome P450 pharmacogenetics in African populations: implications for public health. Expert Opin Drug Metab Toxicol 2014; 10: 769-785.
81. Bains RK. African variation at Cytochrome P450 genes: evolutionary aspects and the implications for the treatment of infectious diseases. Evol Med Public Health 2013; 20131: 118-134.
82. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B et al. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J Infect Dis 2009; 200: 57-65.
83. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002; 300: 399-407.
84. Paganotti GM, Gramolelli S, Tabacchi F, Russo G, Modiano D, Coluzzi M et al. Distribution of human CYP2C8∗2 allele in three different African populations. Malar J 2012; 11: 125.
85. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 2007; 82: 197-203.
86. Capewell P, Cooper A, Clucas C, Weir W, Macleod A. A co-evolutionary arms race: trypanosomes shaping the human genome, humans shaping the trypanosome genome. Parasitology 2015; 142 (Suppl 1): S108-S119.
87. Capewell P, Veitch NJ, Turner CM, Raper J, Berriman M, Hajduk SL et al. Differences between Trypanosoma brucei gambiense groups 1 and 2 in their resistance to killing by trypanolytic factor 1. PLoS Negl Trop Dis 2011; 5: e1287.
88. Pays E, Vanhollebeke B, Uzureau P, Lecordier L, Perez-Morga D. The molecular arms race between African trypanosomes and humans. Nat Rev Microbiol 2014; 12: 575-584.
89. Welburn SC, Molyneux DH, Maudlin I. Beyond Tsetse-implications for research and control of human African trypanosomiasis epidemics. Trends Parasitol 2015; 32: 230-241.
90. Franco JR, Simarro PP, Diarra A, Jannin JG. Epidemiology of human African trypanosomiasis. Clin Epidemiol 2014; 6: 257-275.
91. Welburn SC, Fevre EM, Coleman PG, Odiit M, Maudlin I. Sleeping sickness: a tale of two diseases. Trends Parasitol 2001; 17: 19-24.
92. Wardrop NA, Atkinson PM, Gething PW, Fevre EM, Picozzi K, Kakembo AS et al. Bayesian geostatistical analysis and prediction of Rhodesian human African trypanosomiasis. PLoS Negl Trop Dis 2010; 4: e914.
93. World Health Organization. Cases of sleeping sickness drop to lowest level in 75 years. Geneva, Switzerland 2015. Available at http://www.who.int/trypanosomiasis- african/cases-drop-to-lowest-since-75-years/en/ (accessed on 2 February 2016).
94. World Health Organization. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. WHO technical report series 881: Geneva, Switzerland, 1998.
95. Simarro PP, Diarra A, Ruiz Postigo JA, Franco JR, Jannin JG. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: the way forward. PLoS Negl Trop Dis 2011; 5: e1007.
96. Checchi F, Filipe JA, Haydon DT, Chandramohan D, Chappuis F. Estimates of the duration of the early and late stage of gambiense sleeping sickness. BMC Infect Dis 2008; 8: 16.
97. Odiit M, Kansiime F, Enyaru JC. Duration of symptoms and case fatality of sleeping sickness caused by Trypanosoma brucei rhodesiense in Tororo, Uganda. East Afr Med J 1997; 74: 792-795.
98. Lamour SD, Gomez-Romero M, Vorkas PA, Alibu VP, Saric J, Holmes E et al. Discovery of infection associated metabolic markers in human African trypanosomiasis. PLoS Negl Trop Dis 2015; 9: e0004200.
99. Sternberg JM. Human African trypanosomiasis: clinical presentation and immune response. Parasite Immunol 2004; 26: 469-476.
100. Checchi F, Funk S, Chandramohan D, Haydon DT, Chappuis F. Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis. BMC Res Notes 2015; 8: 292.
101. Lopes MF, Nunes MP, Henriques-Pons A, Giese N, Morse HC 3rd, Davidson WF et al. Increased susceptibility of Fas ligand-deficient gld mice to Trypanosoma cruzi infection due to a Th2-biased host immune response. Eur J Immunol 1999; 29: 81-89.
102. Martins GA, Petkova SB, MacHado FS, Kitsis RN, Weiss LM, Wittner M et al. Fas-FasL interaction modulates nitric oxide production in Trypanosoma cruziinfected mice. Immunology 2001; 103: 122-129.
103. Ribeiro CM, Pontes MJ, Bird S, Chadzinska M, Scheer M, Verburg-van Kemenade BM et al. Trypanosomiasis-induced Th17-like immune responses in carp. PLoS One 2010; 5: e13012.
104. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7: 255-266.
105. Fumagalli M, Pozzoli U, Cagliani R, Comi GP, Bresolin N, Clerici M et al. Genomewide identification of susceptibility alleles for viral infections through a population genetics approach. PLoS Genet 2010; 6: e1000849.
106. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
107. MacLean L, Chisi JE, Odiit M, Gibson WC, Ferris V, Picozzi K et al. Severity of human african trypanosomiasis in East Africa is associated with geographic location, parasite genotype, and host inflammatory cytokine response profile. Infect Immun 2004; 72: 7040-7044.
108. Uzureau P, Uzureau S, Lecordier L, Fontaine F, Tebabi P, Homble F et al. Mechanism of Trypanosoma brucei gambiense resistance to human serum. Nature 2013; 501: 430-434.
109. Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M et al. Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci USA 2014; 111: E2130-E2139.
110. Mukamal KJ, Tremaglio J, Friedman DJ, Ix JH, Kuller LH, Tracy RP et al. APOL1 genotype, kidney and cardiovascular disease, and death in older adults. Arterioscler Thromb Vasc Biol 2016; 36: 398-403.
111. Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 2014; 114: 845-850.
112. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22: 2129-2137.
113. Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in Black South Africans. J Am Soc Nephrol 2015; 26: 2882-2890.
114. Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014; 66: 390-396.
115. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183-2196.
116. Centers for Disease Control and Prevention. Parasites-African Trypanosomiasis (also known as Sleeping Sickness) 2016. Available at: http://www.cdc.gov/para sites/sleepingsickness/health-professionals/ (accessed on 10 October 2016).
117. Arimany-Nardi C, Koepsell H, Pastor-Anglada M. Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions. Pharmacogenomics J 2015; 15: 473-487.
118. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100: 5902-5907.
119. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 1997; 16: 871-881.
120. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol 1997; 51: 913-921.
121. World Health Organization. Global Health Observatory (GHO) data, HIV/AIDS 2015. Available at: http://www.who.int/gho/hiv/en/ (accessed on 10 October 2016).
122. McCutchan FE. Global epidemiology of HIV. J Med Virol 2006; 78 (Suppl 1): S7-s12.
123. Worodria W, Massinga-Loembe M, Mazakpwe D, Luzinda K, Menten J, Van Leth F et al. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr 2011; 58: 32-37.
124. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda R, Catano G et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999; 96: 12004-12009.
125. Schliekelman P, Garner C, Slatkin M. Natural selection and resistance to HIV. Nature 2001; 411: 545-546.
126. Winkler C, An P, O'Brien SJ. Patterns of ethnic diversity among the genes that influence AIDS. Hum Mol Genet 2004; 13 (Spec No)1: R9-19.
127. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-377.
128. Le AQ, Taylor J, Dong W, McCloskey R, Woods C, Danroth R et al. Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR532/32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction. Sci Rep 2015; 5: 17607.
129. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725.
130. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997; 16: 100-103.
131. Hill CM, Littman DR. Natural resistance to HIV? Nature 1996; 382: 668-669.
132. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997; 3: 338-340.
133. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-1243.
134. Eugen-Olsen J, Iversen AK, Garred P, Koppelhus U, Pedersen C, Benfield TL et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11: 305-310.
135. Hummel S, Schmidt D, Kremeyer B, Herrmann B, Oppermann M. Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons. Genes Immun 2005; 6: 371-374.
136. Libert F, Cochaux P, Beckman G, Samson M, Aksenova M, Cao A et al. The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998; 7: 399-406.
137. Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998; 62: 1507-1515.
138. Salem AH, Batzer MA. Distribution of the HIV resistance CCR5-Delta32 allele among Egyptians and Syrians. Mutat Res 2007; 616: 175-180.
139. Bharti D, Kumar A, Mahla RS, Kumar S, Ingle H, Yadav T et al. Low prevalence of CCR5-Delta32, CCR2-64I and SDF1-3'A alleles in the Baiga and Gond tribes of Central India. SpringerPlus 2015; 4: 451.
140. Lu Y, Nerurkar VR, Dashwood WM, Woodward CL, Ablan S, Shikuma CM et al. Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders. Int J Infect Dis 1999; 3: 186-191.
141. Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS Biol 2005; 3: e339.
142. Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc Natl Acad Sci USA 2003; 100: 15276-15279.
143. Lalani AS, Masters J, Zeng W, Barrett J, Pannu R, Everett H et al. Use of chemokine receptors by poxviruses. Science 1999; 286: 1968-1971.
144. Kindberg E, Mickiene A, Ax C, Akerlind B, Vene S, Lindquist L et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197: 266-269.
145. Lim JK, Louie CY, Glaser C, Jean C, Johnson B, Johnson H et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197: 262-265.
146. Smithburn KHT, Burke A. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg 1940; 20: 471-492.
147. Nsanzimana S, Remera E, Kanters S, Chan K, Forrest JI, Ford N et al. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Global Health 2015; 3: e169-e177.
148. Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP et al. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clin Infect Dis 2015; 60: 1102-1110.
149. Bekker LG, Venter F, Cohen K, Goemare E, Van Cutsem G, Boulle A et al. Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir Ther 2014; 19 (Suppl 3): 105-116.
150. Aceti A, Gianserra L, Lambiase L, Pennica A, Teti E. Pharmacogenetics as a tool to tailor antiretroviral therapy: a review. World J Virol 2015; 4: 198-208.
151. Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One 2013; 8: e67946.
152. Swart M, Whitehorn H, Ren Y, Smith P, Ramesar RS, Dandara C. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med Genet 2012; 13: 112.
153. Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, Ueda N et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011; 66: 2350-2361.
154. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A et al. High plasma efavirenz level and CYP2B6∗6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 2012; 12: 499-506.
155. Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D, Ogwal-Okeng J et al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis 2013; 13: 261.
156. Ranade K, Geese WJ, Noor M, Flint O, Tebas P, Mulligan K et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 2008; 22: 1561-1568.
157. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306: 287-300.
158. Mukonzo JK, Roshammar D, Waako P, Andersson M, Fukasawa T, Milani L et al. A novel polymorphism in ABCB1 gene, CYP2B6∗6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 2009; 68: 690-699.
159. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C et al. High prevalence of the CYP2B6 516G→T(∗6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008; 64: 357-365.
160. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009; 13: 1-9.
161. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-1122.
162. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C et al. Association between presence of HLA-B∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
163. Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N Engl J Med 2010; 363: 1551-1558.
164. Oluka MN, Okalebo FA, Guantai AN, McClelland RS, Graham SM. Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study. AIDS Res Ther 2015; 12: 10.
165. Mhandire D, Lacerda M, Castel S, Mhandire K, Zhou D, Swart M et al. Effects of CYP2B6 and CYP1A2 genetic variation on nevirapine plasma concentration and pharmacodynamics as measured by CD4 cell count in Zimbabwean HIV-infected patients. Omics 2015; 19: 553-562.
166. Monath TP, Newhouse VF, Kemp GE, Setzer HW, Cacciapuoti A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 1974; 185: 263-265.
167. Mylne AQ, Pigott DM, Longbottom J, Shearer F, Duda KA, Messina JP et al. Mapping the zoonotic niche of Lassa fever in Africa. Trans R Soc Trop Med Hyg 2015; 109: 483-492.
168. Frame JD, Baldwin JM Jr., Gocke DJ, Troup JM. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg 1970; 19: 670-676.
169. Buckley SM, Casals J. Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. Am J Trop Med Hyg 1970; 19: 680-691.
170. Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH et al. Genetic diversity among Lassa virus strains. J Virol 2000; 74: 6992-7004.
171. Fichet-Calvet E, Rogers DJ. Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis 2009; 3: e388.
172. Atkin S, Anaraki S, Gothard P, Walsh A, Brown D, Gopal R et al. The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. Euro Surveil 2009; 14: pii.
173. Gunther S, Emmerich P, Laue T, Kuhle O, Asper M, Jung A et al. Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis 2000; 6: 466-476.
174. Andersen KG, Shylakhter I, Tabrizi S, Grossman SR, Happi CT, Sabeti PC. Genomewide scans provide evidence for positive selection of genes implicated in Lassa fever. Philos Trans R Soc Lond B Biol Sci 2012; 367: 868-877.
175. McCormick JB. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med Microbiol Immunol 1986; 175: 153-155.
176. Cao W, Henry MD, Borrow P, Yamada H, Elder JH, Ravkov EV et al. Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998; 282: 2079-2081.
177. Kunz S, Rojek JM, Kanagawa M, Spiropoulou CF, Barresi R, Campbell KP et al. Posttranslational modification of alpha-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J Virol 2005; 79: 14282-14296.
178. Sabeti PC, Varilly P, Fry B, Lohmueller J, Hostetter E, Cotsapas C et al. Genomewide detection and characterization of positive selection in human populations. Nature 2007; 449: 913-918.
179. Fumagalli M, Cagliani R, Riva S, Pozzoli U, Biasin M, Piacentini L et al. Population genetics of IFIH1: ancient population structure, local selection, and implications for susceptibility to type 1 diabetes. Mol Biol Evol 2010; 27: 2555-2566.
180. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314: 20-26.
181. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
182. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
183. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
184. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
185. World Health Organization. Global tuberculosis report 2015. Available at: http:// apps.who.int/iris/bitstream/10665/191102/1/9789241565059-eng.pdf (accessed on 10 October 2016).
186. Wamala D, Buteme HK, Kirimunda S, Kallenius G, Joloba M. Association between human leukocyte antigen class II and pulmonary tuberculosis due to mycobacterium tuberculosis in Uganda. BMC Infect Dis 2016; 16: 23.
187. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 2003; 16: 463-496.
188. Moller M, Hoal EG. Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis. Tuberculosis 2010; 90: 71-83.
189. Bellamy R, Beyers N, McAdam KP, Ruwende C, Gie R, Samaai P et al. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proc Natl Acad Sci USA 2000; 97: 8005-8009.
190. Kettaneh A, Seng L, Tiev KP, Toledano C, Fabre B, Cabane J. Human leukocyte antigens and susceptibility to tuberculosis: a meta-analysis of case-control studies. Int J Tuberc Lung Dis 2006; 10: 717-725.
191. Dubaniewicz A, Lewko B, Moszkowska G, Zamorska B, Stepinski J. Molecular subtypes of the HLA-DR antigens in pulmonary tuberculosis. Int J Infect Dis 2000; 4: 129-133.
192. Yuliwulandari R, Sachrowardi Q, Nakajima H, Kashiwase K, Hirayasu K, Mabuchi A et al. Association of HLA-A,-B, and-DRB1 with pulmonary tuberculosis in western Javanese Indonesia. Hum Immunol 2010; 71: 697-701.
193. Mishra G, Kumar N, Kaur G, Jain S, Tiwari PK, Mehra NK. Distribution of HLA-A, B and DRB1 alleles in Sahariya tribe of North Central India: an association with pulmonary tuberculosis. Infect Genet Evol 2014; 22: 175-182.
194. Lombard Z, Brune AE, Hoal EG, Babb C, Van Helden PD, Epplen JT et al. HLA class II disease associations in southern Africa. Tissue Antigens 2006; 67: 97-110.
195. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707.
196. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202.
197. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2012; 16: 589-595.
198. Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 2011; 55: 4122-4127.
199. Behar DM, Kedem E, Rosset S, Haileselassie Y, Tzur S, Kra-Oz Z et al. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am J Nephrol 2011; 34: 452-459.
200. Adeyemo AA, Tekola-Ayele F, Doumatey AP, Bentley AR, Chen G, Huang H et al. Evaluation of genome wide association study associated type 2 diabetes susceptibility loci in Sub Saharan Africans. Front Genet 2015; 6: 335.
201. Ko WY, Rajan P, Gomez F, Scheinfeldt L, An P, Winkler CA et al. Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations. Am J Hum Genet 2013; 93: 54-66.
202. Pagani L, Kivisild T, Tarekegn A, Ekong R, Plaster C, Gallego Romero I et al. Ethiopian genetic diversity reveals linguistic stratification and complex influences on the Ethiopian gene pool. Am J Hum Genet 2012; 91: 83-96.